Reference health
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
28/28 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 28 checked references that resolve
resolves10.1038/bjc.2017.94
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
resolves10.1200/JCO.2003.10.065
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
resolves10.1016/j.ejca.2019.09.028
Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France
resolves10.1016/j.ejca.2003.12.004
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
resolves10.1002/cpt.911
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
resolves10.1371/journal.pone.0175998
New advances in DPYD genotype and risk of severe toxicity under capecitabine
resolves10.1002/ijc.29654
Clinical validity of a <scp><i>DPYD</i></scp>‐based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
resolves10.2217/pgs.13.116
<i>DPYD</i>
IVS14+1G>A and 2846A>T Genotyping for the Prediction of Severe Fluoropyrimidine-Related Toxicity: A Meta-Analysis
resolves10.1016/S1470-2045(18)30686-7
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
resolves10.1016/S1470-2045(15)00286-7
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
resolves10.2217/pgs.14.126
Predicting 5-Fluorouracil Toxicity: DPD Genotype and 5,6-Dihydrouracil: Uracil Ratio
resolves10.1016/j.canlet.2006.09.006
5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
resolves10.1053/j.seminoncol.2017.02.008
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
resolves10.2174/2212697X04666170817123425
Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients
resolves10.1111/bcp.12790
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase‐driven adaptive dosing of 5‐FU in patients with digestive cancer
resolves10.1007/s00280-010-1282-4
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
resolves10.1016/j.jpba.2016.04.039
Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma
resolves10.1093/chromsci/bms085
Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma
resolves10.1016/j.bulcan.2018.02.001
Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx
resolves10.1200/JCO.1999.17.4.1105
Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage
resolves10.1016/j.clinbiochem.2018.04.001
DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity
resolves10.1016/j.ctrv.2016.08.002
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?
resolves10.1053/j.seminoncol.2017.06.001
Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing
resolves10.1016/j.clinbiochem.2016.07.004
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies
resolves10.1371/journal.pone.0163105
Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
resolves10.1016/j.clcc.2011.03.015
Body Surface Area–based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens
The 1 reference without a DOI — listed, not checked
no DOI — not checkedvan Kuilenburg, A. B., Haasjes, J., Richel, D. J., Zoetekouw, L., Van Lenthe, H., De Abreu, R. A. et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6, 4705–4712 (2000).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/s41416-020-0962-z"><img src="https://citestamp.com/citestamped/10.1038/s41416-020-0962-z/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/s41416-020-0962-z)